THE 5-SECOND TRICK FOR MY-1B

There were no clinically significant dissimilarities during the pharmacokinetics of both midazolam (CYP3A4 substrate) or repaglinide (CYP2C8 substrate) when utilized concomitantly with finerenone. Various doses of 40 mg finerenone at the time-each day had no clinically applicable effect on AUC or Cmax of your BCRP and OATP substrate rosuvastatin.Ov